DIRA Clinical Trial
Official title:
A Pilot Open-Label Study of Rilonacept (Arcalyst) in the Deficiency of the Interleukin-1 Receptor Antagonist (DIRA)
Background:
- Deficiency of the IL-1 receptor antagonist (DIRA) is a condition that causes repeated
episodes of inflammation. People with DIRA can have rashes, fever, and joint pain. Most
treatments for DIRA are intended to control the immune system to stop these inflammations.
There are drugs that can treat DIRA, but they have to be given daily as injections.
Researchers want to try another drug, rilonacept, as a treatment for DIRA. It needs to be
given only once a week. Rilonacept will be given to individuals who are at least 3 months old
and who have DIRA.
Objectives:
- To test the safety and effectiveness of rilonacept for children and adults with DIRA.
Eligibility:
- Individuals at least 3 months old who have DIRA.
Design:
- Participants will be screened with a physical exam and medical history. Blood and urine
samples will be collected. Other tests to study pain and movement will be given. Imaging
studies such as bone density scans and x-rays may also be taken.
- Participants will have a minimum of four to five study visits over 12 months. Those who
are on different anti-inflammatory drugs (such as anakinra) will stop taking them before
beginning the study visits.
- Participants will have rilonacept injections weekly while on this study. The dose will
be adjusted as needed to help treat the DIRA symptoms. Participants will keep a diary to
monitor their symptoms and any side effects.
- Treatment with rilonacept will be given for 1 year. Participants will have study visits
to monitor the treatment. They will provide blood samples and have other tests at these
study visits.
Autoinflammatory diseases are illnesses characterized by episodes of inflammation that,
unlike autoimmune disorders, lack the production of high titer autoantibodies or
antigen-specific T cells. There is growing genetic and clinical evidence that specific
cytokine pathways are dysregulated. Monogenic defects in the IL-1 pathway cause cryopyrin
associated periodic syndromes (CAPS) and deficiency of the IL-1 receptor antagonist (DIRA),
the latter is caused by mutations affecting the IL-1-receptor antagonist gene (IL1RN). Both
disorders respond with complete resolution of the inflammatory response to treatment with the
short acting IL-1 blocking agent anakinra. This exploratory study aims to examine the utility
of the long acting IL-1 inhibitor rilonacept (rilonacept; Regeneron Pharmaceuticals, Inc.)
This pilot study is designed to address: 1) the utility and dosage of rilonacept needed to
achieve inflammatory remission in children with DIRA who have shown a response to treatment
with anakinra [Kineret[registered]]; and 2) to evaluate the safety and pharmacokinetics in
young children on rilonacept.
Rilonacept is a recombinant fusion protein with picomolar affinity for IL-1 and a half-life
of approximately 7.5 days in humans. It is approved by the Food and Drug Administration (FDA)
for the treatment of adults and children 12 years of age and older with Cryopyrin-Associated
Periodic Syndromes (CAPS), and was tested in the clinically milder forms of CAPS including
Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS).
In this study, clinical, and laboratory parameters will initially be measured at baseline
following a withdrawal of anakinra for 24 hours. Subjects will receive a course of therapy
with rilonacept that is predicted to induce inflammatory remission. Clinical and laboratory
measures of inflammation will be assessed; rilonacept dose escalation will be implemented as
necessary to achieve clinical and laboratory remission. Subjects will remain on study for 12
months and primary end point will be evaluated at 6 months.
Those subjects who complete the 1-year treatment period and maintain improved clinical and
laboratory parameters compared to baseline values, may continue to receive study medication
at their current dose. Principal investigator will help to obtain insurance coverage for
rilonacept for their continued treatment, and will discuss with Regeneron Pharmaceuticals,
Inc. for additional supplies of rilonacept for these subjects.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT02974595 -
Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still'S-like Diseases, and Other Undifferentiated Autoinflammatory Diseases)
|